Bioverativ Class Seeks Sanctions For Insiders' Trades
Stockholders who recently won a partial $84 million award in a challenge to an $11.6 billion sale of biomedical venture Bioverativ to Sanofi Inc. have asked Delaware's Court of Chancery to...To view the full article, register now.
Already a subscriber? Click here to view full article